Vigamox Shortage Update: What Patients Need to Know in 2026

If you've been searching for information about a Vigamox shortage, you're not alone. Many patients and caregivers contact pharmacies to fill a Vigamox (moxifloxacin ophthalmic 0.5%) prescription, only to be told the medication is out of stock. This guide gives you a clear, current picture of Vigamox availability in 2026 and what it means for you.

Current Vigamox Shortage Status in 2026

As of 2026, Vigamox (moxifloxacin ophthalmic solution 0.5%) is NOT listed as an active shortage on the FDA Drug Shortages database or the ASHP (American Society of Health-System Pharmacists) shortage list. This means there is no widespread, documented national shortage of this medication.

However — and this is important — the absence of a national shortage doesn't mean the medication is easy to find at every pharmacy. Patients routinely encounter localized out-of-stock situations caused by demand spikes, distributor delays, and the natural ebb and flow of pharmacy inventory management.

Why Are Some Pharmacies Out of Vigamox?

Even when the overall supply chain is healthy, individual pharmacies can run low due to:

Seasonal demand spikes. Back-to-school season (August–September) and cold/flu season drive sharp increases in pink eye cases. Pharmacies that didn't increase orders ahead of these periods run out quickly.

Ophthalmic surgical volume. Moxifloxacin is widely used before and after cataract surgery and other eye procedures. High-volume surgical months can deplete local pharmacy stock.

Distributor logistics delays. National supply may be fine, but regional distribution bottlenecks can delay restocking at individual pharmacy locations by a few days.

Brand-generic mix. Brand-name Vigamox and generic moxifloxacin may not both be in stock at the same pharmacy. Your prescription may specify one, but only the other is available.

Vigamox Supply History: How We Got Here

Vigamox was originally developed and manufactured by Alcon and later distributed by Novartis Pharmaceuticals. Its foundational U.S. patent expired in 2015, with formulation patents expiring by 2018. This opened the market to generic competition, and manufacturers including Teva, Alembic, and Bausch Health now produce FDA-approved generic moxifloxacin ophthalmic 0.5%.

Multiple generic suppliers mean the market is more resilient than single-source medications. But generic ophthalmic drugs still have a limited number of sterile manufacturing facilities globally, and any quality issues at a major manufacturer can affect supply for weeks.

What Should Patients Do Right Now?

Don't panic. There is no active national shortage. Your pharmacy may simply be temporarily out of stock.

Ask about the generic. If your prescription says "Vigamox" (brand), ask if generic moxifloxacin ophthalmic 0.5% is available. It's therapeutically equivalent and often much cheaper.

Use medfinder to locate a pharmacy with your medication in stock. medfinder calls pharmacies in your area and texts you which ones can fill your prescription — faster than calling yourself.

Ask your prescriber about alternatives. If moxifloxacin is hard to find at multiple pharmacies nearby, ciprofloxacin ophthalmic, tobramycin, or besifloxacin may be suitable alternatives.

Checking the Latest Shortage Status Yourself

You can check current drug shortage listings directly on the FDA Drug Shortages database. Search for "moxifloxacin ophthalmic" to see if any manufacturer has reported a shortage. These listings are updated regularly and are the authoritative source.

The Bottom Line for Patients in 2026

Vigamox is generally available in 2026, but individual pharmacies can run out temporarily. The key is knowing how to find it quickly. Use medfinder to check pharmacy availability or read our guide on how to find Vigamox in stock near you for step-by-step tips.